Back to search page

BRCN20201103001

Chinese pharmaceutical company seeks partnership on endocrine, cardio-cerebrovascular, ocular, autoimmune diseases and tumor related drugs under license agreement

COMMERCIAL PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

This Chinese pharmaceutical company has cooperation with many domestic pharmaceutical companies and industry funds. It has a mature platform for the R&D and production of macromolecule and small-molecule drugs. It is seeking innovative drugs in endocrine, cardio-cerebrovascular, ocular and autoimmune diseases and tumors. Those drugs can either be large-molecule, or small-molecule, or cell therapy drugs from Europe. Ideal cooperation could be via license agreement.


FULL DESCRIPTION

The Chinese company is a pharmaceutical company with a number of mature drug production channels. The products cover a wide range of diseases, such as tumors, cardiovascular and cerebrovascular diseases, cardio-cerebrovascular disease, and nervous system diseases. A number of drugs are currently on various stages of clinical trials. The Chinese company plans to bring in some of the new drug projects, specifically endocrine, cardio-cerebrovascular, ocular and autoimmune diseases and tumor related drugs from the European Union via a patent license agreement or patent transfer.
With patent licensing partnership, the European company transfers the rights of R&D and sales of the selected drugs in China to the Chinese company, and the Chinese company is obliged to pay the license fee of the project in a lump sum to the European side, or pay by milestone according to different stages of the project as specified in the agreement.
The target European company should have a mature drug development team. The target innovative drug program should be Investigational New Drugs (IND) to treat endocrine, cardio-cerebrovascular, ocular and autoimmune related diseases and tumors approved in Europe by the European Medicines Agency (EMA) or in the United States by the Food and Drug Administration (FDA ), with pharmacodynamics, pharmacokinetics, and safety evaluation.


Partner expertise sought:

- Type of partner sought: The Chinese company plans to introduce endocrine, cardio-cerebrovascular, ocular and autoimmune diseases and tumor related drugs from the European Union into China via a patent license agreement or patent transfer.
The ideal drug program should be Investigational New Drugs (IND) to treat endocrine, cardio-cerebrovascular, ocular and autoimmune diseases and tumors approved by the European Medicines Agency (EMA) or by the U.S. Food and Drug Administration (FDA ), with pharmacodynamics, pharmacokinetics, and safety evaluation.
- Specific area of activity of the partner: The target European company should have a mature drug development team. Under the patent license agreement, the European company transfers the rights of R&D and sales of the selected drugs in China to the Chinese company, and the Chinese company shall pay the license fee in a lump sum or by milestone according to different stages of the project.


Advantages & innovations:

The Chinese company cooperates with a number of domestic and foreign pharmaceutical companies. The company has passed the Chinese Good Manufacturing Practice (GMP) certification, and has a number of mature research and development and production pipelines. A number of products have received the New Drug Application (NDA) approval, and a number of products are in clinical trials. Its products are involved in treatment of tumor, cardiovascular and cerebrovascular, endocrine and other diseases.


Development Stage:

Already on the market

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
CHINA
Profile date
18/11/2020
Deadline
18/11/2021

PARTNERSHIP(S) SOUGHT

License agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Life Sciences \ Biosciences and Health \ Drug Discovery and Drug Development
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Pharmaceutical Products / Drugs
COMMERCIAL KEYWORDS
none...
MARKET KEYWORDS
MEDICAL/HEALTH RELATED / Clinical Medicine / Endocrinology

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number BRCN20201103001